Price$40.26+1.05 (+2.67%)
01:30 PM07:45 PM
News · 26 weeks92-17%
2026-01-182026-07-12
Mix5690d
- SEC Filings20(36%)
- Insider20(36%)
- Other8(14%)
- Analyst3(5%)
- Offering3(5%)
- Earnings2(4%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by uniQure N.V.SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)
- INSIDERCEO, Managing Director Kapusta Matthew C exercised 21,082 units of Ordinary Shares at a strike of $19.39 and sold $952,051 worth of Ordinary Shares (21,082 units at $45.16) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Medical Officer Abi-Saab Walid exercised 10,000 units of Ordinary Shares at a strike of $5.59 and sold $1,392,600 worth of Ordinary Shares (30,000 units at $46.42) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 148,235 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Kaye Jack exercised 21,167 units of Ordinary Shares at a strike of $23.44 and sold $983,030 worth of Ordinary Shares (21,167 units at $46.44) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERChief Medical Officer Abi-Saab Walid sold $67,197 worth of Ordinary Shares (1,434 units at $46.86), decreasing direct ownership by 0.85% to 168,235 units (SEC Form 4) (for withholding tax)4 - uniQure N.V. (0001590560) (Issuer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERCEO, Managing Director Kapusta Matthew C exercised 32,844 units of Ordinary Shares at a strike of $31.71 and sold $1,771,174 worth of Ordinary Shares (35,412 units at $50.02) as part of a pre-agreed trading plan, decreasing direct ownership by 0.49% to 519,227 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- PRuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesLEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- SECuniQure N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- SECSEC Form 424B5 filed by uniQure N.V.424B5 - uniQure N.V. (0001590560) (Filer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- PRuniQure Announces Pricing of Upsized $225 Million Public OfferingLEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $225 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-d
- PRuniQure Announces $150 Million Proposed Public OfferingLEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its ordinary shares on the same terms and conditions. The offering is subject to market and othe
- SECSEC Form 424B5 filed by uniQure N.V.424B5 - uniQure N.V. (0001590560) (Filer)
- INSIDERCEO, Managing Director Kapusta Matthew C exercised 67,237 units of Ordinary Shares at a strike of $20.24 and sold $9,371,612 worth of Ordinary Shares (206,100 units at $45.47) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 521,795 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Balachandran Madhavan exercised 11,685 units of Ordinary Shares at a strike of $24.97 and sold $526,485 worth of Ordinary Shares (11,685 units at $45.06) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Kaye Jack exercised 5,295 units of Ordinary Shares at a strike of $31.71 and sold $225,408 worth of Ordinary Shares (5,295 units at $42.57) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- SECuniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced initial six-month follow-up data on the first, low dose cohort of six patients in its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, for the treatment of refractory mesial temporal lobe epilepsy (MTLE). The data will be presented today, Friday, June 19, 2026, at the Epilepsy Foundation Pipeli
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- ANALYSTuniQure upgraded by Barclays with a new price targetBarclays upgraded uniQure from Equal Weight to Overweight and set a new price target of $65.00
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERDirector Balachandran Madhavan exercised 10,000 units of Ordinary Shares at a strike of $8.49 and sold $278,500 worth of Ordinary Shares (10,000 units at $27.85) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
QURE FAQ
7 questionsWhat does uniQure N.V. do?
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated...Where does QURE stock trade?
uniQure N.V. (QURE) is listed on NASDAQ.What sector and industry is QURE in?
uniQure N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did uniQure N.V. go public?
uniQure N.V. (QURE) completed its IPO in 2014.What are analysts saying about QURE?
uniQure N.V. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-06-18. Recent price targets range from $1200.00 to $3500.00.What companies are similar to QURE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare QURE side-by-side with any of them on Quantisnow.How can I track QURE on Quantisnow?
Quantisnow aggregates uniQure N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QURE to receive live email and push alerts on every new disclosure.